Investment Rating - The investment rating for the company is maintained as "Buy" with a target price of RMB 29.12 [1][7]. Core Views - The company has shown a positive growth trajectory in its revenue and profit, with a notable increase in the contribution from high-margin CDMO business [2][3]. - The company’s CDMO business achieved revenue of RMB 22.91 billion in the first half of 2025, reflecting a year-on-year growth of 16% [3]. - The company is expanding its new business capabilities, with significant progress in peptide and conjugated drug production, as well as small nucleic acid projects [4]. Summary by Sections Financial Performance - In the first half of 2025, the company reported revenue of RMB 28.71 billion, a year-on-year increase of 4%, and a net profit attributable to the parent company of RMB 5.26 billion, up 11% year-on-year [1]. - The second quarter of 2025 saw revenue of RMB 13.81 billion, with net profit increasing by 16% year-on-year [1]. CDMO Business - The CDMO business is a key growth driver, with a revenue contribution increasing from 71% in 2024 to 80% in the first half of 2025, leading to an improvement in gross margin from 35% to 37% [2]. - The company has a robust project pipeline, with 1,086 projects in clinical phases and 38 in commercialization as of the first half of 2025 [3]. New Business Development - The company has made strides in building capabilities for new business areas, including the expansion of facilities for peptide and conjugated drugs, and has onboarded over 20 new clients in the first half of 2025 [4]. Profit Forecast and Valuation - The forecast for net profit attributable to the parent company for 2025-2027 is RMB 9.14 billion, RMB 9.52 billion, and RMB 9.74 billion respectively, with corresponding EPS of RMB 1.03, RMB 1.07, and RMB 1.09 [5][10]. - The company is valued at RMB 259 billion using the SOTP method, with a target price of RMB 29.12 based on a total share count of 889 million [5][12].

Investment Rating - The report maintains a "Buy" rating for the company [4][6]. Core Views - The company is expected to face a revenue decline of approximately 38.3% to 41.9% year-on-year for the first half of 2025, with a projected net profit decrease of 23% to 24% [1][2]. - The company is actively responding to external pressures by adjusting its payment and delivery schedules, focusing on channel health, and launching strategic flagship products [2][3]. - Despite the challenges, the company’s brand possesses unique characteristics and a diversified marketing system, which may support regional and capacity expansion [1][4]. Summary by Sections Financial Performance - For the first half of 2025, the company anticipates revenue between 24.0 to 25.5 billion RMB, with a year-on-year decline of 38.3% to 41.9% [1]. - The expected net profit attributable to the parent company is around 5.7 to 5.8 billion RMB, reflecting a decrease of 23% to 24% year-on-year [2]. - Adjusted net profit is projected to be approximately 6.1 to 6.2 billion RMB, indicating a decline of 39% to 40% [2]. Strategic Initiatives - The company is launching new strategic flagship products, including "珍 10" and "大珍·珍酒," to capture market share in both mid-range and high-end segments [3]. - Efforts are being made to solidify the competitive position of existing flagship products and enhance penetration in core markets [3]. - The company aims to tap into emerging consumer trends and scenarios, such as products for birthdays and weddings [3]. Future Outlook - The revenue forecast for 2025 to 2027 has been adjusted downwards by 27% across the board, with expected earnings per share (EPS) of 0.34, 0.38, and 0.44 RMB for the respective years [4][12]. - The target price is set at 8.04 HKD, based on a price-to-earnings (PE) ratio of 22x for 2025 [4][6]. - The company is expected to maintain a relatively stable net profit margin despite the adjustments, reflecting confidence in its core business profitability [12].

Investment Rating - The investment rating for the company is maintained as "Buy" with a target price of HKD 100.00 [5] Core Views - The company is expected to see significant revenue growth in the first half of 2025, with projected revenue between RMB 4.09 billion and RMB 4.11 billion, representing a year-on-year increase of 16.8% to 17.3%. Net profit is anticipated to be around RMB 540 million to RMB 560 million, reflecting a year-on-year growth of 30.9% to 35.8% [5][6] - The growth in revenue and profit is primarily driven by the multi-category layout of the Han Shu brand and substantial growth in the Newpage brand, which focuses on infant skincare [5][6] - The company is expected to maintain its competitive advantage in its price segment and expand its product categories, leveraging its multi-brand matrix for new opportunities [5][8] Financial Projections - Revenue projections for the company are as follows: - 2024: RMB 6,793 million (+62.08%) - 2025E: RMB 8,502 million (+25.16%) - 2026E: RMB 10,422 million (+22.59%) - 2027E: RMB 12,668 million (+21.55%) [4] - Net profit projections are: - 2024: RMB 781.21 million (+69.42%) - 2025E: RMB 1,020 million (+30.53%) - 2026E: RMB 1,283 million (+25.86%) - 2027E: RMB 1,559 million (+21.51%) [4] - The expected EPS for the upcoming years is: - 2024: RMB 1.96 - 2025E: RMB 2.56 - 2026E: RMB 3.22 - 2027E: RMB 3.92 [4] Market Performance - In the first half of 2025, Han Shu's online GMV reached RMB 5.2 billion, a year-on-year increase of 19%, ranking fourth among domestic brands [6] - The brand's performance on the Douyin platform showed a significant increase in GMV, achieving RMB 456 million in July 2025, a year-on-year growth of 68.7% [6] - The Newpage brand also demonstrated strong growth, with GMV of RMB 341 million in the first half of 2025, reflecting a year-on-year increase of 128% [6][8]

Investment Rating - The report maintains an "Overweight" rating for the transportation sector [8] Core Views - The express delivery sector is expected to see significant profit recovery due to an early price increase trend, while the aviation sector is still at the bottom of the economic cycle, with potential for mid-term improvements in supply and demand [1][2][3] Summary by Sections Express Delivery - In June, the retail sales and express delivery volumes showed year-on-year increases of 5.3% and 15.8% respectively, although the growth rate has slowed compared to May [3] - The price increase trend has started in core grain-producing areas, which could lead to significant profit recovery for express delivery companies if this trend spreads across all price ranges [3][10] - Key companies recommended include ZTO Express, YTO Express, and Shunfeng Express [10] Aviation - The summer travel season has shown weak performance, with domestic ticket prices declining by 7.5% year-on-year, despite a slight increase in passenger load factor [2][16] - The aviation sector is currently at a low point, but improvements in supply growth and demand could enhance profitability in the medium term [26] - Recommended stocks include China National Aviation and Huaxia Airlines, which are expected to benefit from supply-demand improvements [26] Logistics - The logistics sector is experiencing an early price increase in express delivery, and the bulk supply chain is expected to recover alongside rising commodity prices [3][65] - The cross-border e-commerce logistics sector is showing resilience as tariff impacts diminish [3] Shipping and Ports - In July, shipping rates for container shipping and oil transport declined, while dry bulk shipping rates increased due to seasonal demand [35][36] - The report anticipates stable supply-demand dynamics in August, with shipping rates expected to remain volatile [35] Road and Rail - The road transport sector is under pressure due to rising risk preferences and potential impacts from upstream industry dynamics [5] - Rail transport is expected to see flat growth in passenger traffic during the summer, with ongoing observations needed for the impact of upstream industry changes [5]

Group 1: Steel Industry - The steel industry is expected to benefit from self-initiated production cuts, with industry prosperity bottoming out in Q3 2024. If the anti-involution policy promotes crude steel production cuts, it could further enhance profit recovery [2][3] - The current phase of the steel sector is characterized by policy expectation trading and fundamental improvement, similar to the previous demand downturn cycle [2][3] - The adjustment in the Chinese steel industry may resemble a prolonged battle, drawing parallels with Japan's steel development history [2] Group 2: Saint Bella (2508 HK) - Saint Bella is the largest postpartum care and recovery brand group in Asia and China, with 96 maternity centers in 30 cities globally as of June 2025. The company is rated "Buy" with a target price of HKD 9.76, corresponding to a 27X PE for 2026 [3][14] - The company is expected to achieve a revenue and adjusted net profit CAGR of 28% and 94% respectively from 2025 to 2027, driven by stable same-store growth and rapid store expansion [3] - Saint Bella aims to expand its family care and women's health product lines globally, leveraging its multi-brand and platform capabilities [3] Group 3: Yum China (9987 HK) - Yum China reported Q2 2025 revenue of USD 2.787 billion, a year-on-year increase of 4%, and an operating profit of USD 304 million, exceeding expectations [5] - The company maintains a target of opening 1,600 to 1,800 new stores in 2025, with a focus on sustaining same-store sales growth in the second half of the year [5] - The operating profit margin improved to 10.9%, reflecting the resilience of the leading brand [5] Group 4: Techtronic Industries (669 HK) - Techtronic Industries achieved a revenue of USD 7.833 billion in H1 2025, a year-on-year increase of 7.1%, with a net profit of USD 628 million, up 14.2% [6] - The growth is attributed to strong sales of flagship brands Milwaukee and RYOBI, alongside a strategic reduction in non-core business investments [6] - The company is positioned as a leading global brand in power tools and outdoor products, with a favorable long-term growth outlook [6] Group 5: Dongmu Co., Ltd. (600114 CH) - Dongmu Co., Ltd. reported H1 2025 revenue of CNY 2.930 billion, a year-on-year increase of 24.51%, and a net profit of CNY 261 million, up 37.61% [7] - The strong performance is driven by robust demand in the automotive and home appliance sectors [7] - The company is recognized as a leader in the powder metallurgy industry, maintaining an "Overweight" rating [7] Group 6: Zhongchong Co., Ltd. (002891 CH) - Zhongchong Co., Ltd. achieved H1 2025 revenue of CNY 2.432 billion, a year-on-year increase of 24.32%, with a net profit of CNY 203 million, up 42.56% [10] - The company benefits from strong domestic sales growth of 39% and an 18% increase in overseas sales due to capacity expansion [10] - The target price for 2025 is set at CNY 79.52, maintaining a "Buy" rating [10]

Investment Rating - The report maintains a "Buy" rating for the company [7][5]. Core Views - The company reported strong same-store performance in Q2 2025, with operating profit exceeding expectations, showcasing resilience as a market leader [1][2]. - The company aims to open 1,600 to 1,800 new stores in 2025, with a focus on increasing the proportion of franchise stores [4][3]. - The target price is set at HKD 444.80 or USD 56.66, reflecting a slight adjustment in revenue and net profit forecasts for 2025-2027 [5][8]. Financial Performance - Q2 2025 revenue reached USD 2.787 billion, a year-over-year increase of 4%, while the first half of 2025 revenue was USD 5.768 billion, up 2% [1]. - Q2 operating profit was USD 304 million, a 14% increase year-over-year, with an operating margin of 10.9% [2][1]. - The company achieved a net profit of USD 215 million in Q2, with a net profit margin of 7.7% [1]. Store Expansion and Capital Expenditure - As of June 30, 2025, the company had 16,978 stores, with 336 new stores opened in the quarter, achieving the target for new franchise store openings [3][4]. - The capital expenditure per store has been optimized, with KFC and Pizza Hut's CAPEX reduced to USD 140,000 and USD 110,000-120,000 respectively [3][4]. Future Outlook - The company expects to maintain steady same-store sales growth in the second half of 2025, supported by cost structure optimization and ongoing store type iterations [1][4]. - The forecast for operating profit margin is a moderate increase for the full year, with expectations for improved free cash flow starting in 2025 due to reduced capital expenditures [4][5].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 132.59 [6][5]. Core Insights - The company reported strong performance in H1 2025, achieving revenue of USD 7.833 billion (yoy +7.1%) and a net profit of USD 628 million (yoy +14.2%), with a net profit margin of 8.0% (yoy +0.5pct) [1][3]. - Growth is driven by flagship brands Milwaukee and RYOBI, with a strategic focus on high-end brands and improved operational efficiency [1][4]. - The company is positioned as a global leader in electric tools and outdoor power equipment (OPE), benefiting from a diversified global production capacity to navigate trade challenges [1][4]. Revenue Performance - The electric tools segment generated USD 7.425 billion in H1 2025, up 7.9% yoy, with Milwaukee's revenue increasing by 11.9% and RYOBI's by 8.7% [2]. - The floor care and cleaning segment saw revenue decline to USD 408 million (yoy -4.8%), but operating profit increased by 3.6% to USD 9.7 million due to a shift towards rechargeable products [2]. Profitability Analysis - The company's gross margin for H1 2025 was 40.3% (yoy +0.3pct), attributed to the higher contribution from profitable brands and improved operational efficiency [3]. - Total operating expenses were USD 2.452 billion (yoy +6.5%), with a corresponding expense ratio of 31.3% (yoy -0.2pct) [3]. Brand and Technology Advantage - The company has a strong brand and technological edge, with 13 sub-brands catering to various consumer segments and a commitment to lithium battery upgrades [4]. - Global production facilities are strategically located, with 39% of capacity in China and significant portions in Vietnam, the US, and Mexico, allowing flexibility in response to tariff disruptions [4]. Earnings Forecast and Valuation - The company’s net profit is projected to be USD 1.293 billion, USD 1.473 billion, and USD 1.737 billion for 2025, 2026, and 2027 respectively, with corresponding EPS of USD 0.71, USD 0.80, and USD 0.95 [5][10]. - The report assigns a target PE of 24x for 2025, reflecting the company's leading position and consistent profitability improvements [5][10].

Investment Rating - The report initiates coverage on Saint Bella with a "Buy" rating and a target price of HKD 9.76, corresponding to a 27X PE for 2026E [1][5][7]. Core Insights - Saint Bella is the largest postpartum care and recovery brand group in Asia and China, with 96 centers in 30 cities globally as of June 2025. The company is expected to achieve a revenue and adjusted net profit CAGR of 28% and 94% from 2025 to 2027, respectively [1][19]. - The company is positioned in a growth phase characterized by stable same-store growth and rapid expansion, leveraging its unique high-end service brand and standardized operational capabilities [1][19]. - The report highlights the company's strategy of horizontal global expansion and vertical integration into family care and women's health food sectors, aiming to enhance its full-cycle family care platform [1][3]. Summary by Sections Company Overview - Saint Bella recorded a revenue of RMB 798.67 million in 2024, with a year-on-year growth of 42.64%. The adjusted net profit for the same year is projected at RMB 120.69 million, marking a significant recovery from previous losses [11][19]. Competitive Advantages - The company has established a "brand-scale" positive cycle through a unique high-end service model, innovative supply chain management, and effective customer retention strategies. It holds a 1.2% market share, leading the industry [2][3]. - The operational model includes a light-asset approach with flexible leasing and a proprietary nursing team, enhancing service quality and operational efficiency [2][21]. Growth Strategy - Short to medium-term focus on domestic and international expansion, with a target of 267-316 centers in China. The company plans to utilize its established brand and operational model to penetrate international markets [3][19]. - Long-term vision includes transforming into a comprehensive family health management platform, with new business segments expected to grow at over 30% annually [3][19]. Financial Projections - The report forecasts adjusted net profits of RMB 1.21 billion, RMB 2.05 billion, and RMB 3.06 billion for 2025, 2026, and 2027, respectively, with corresponding adjusted EPS of RMB 0.19, RMB 0.33, and RMB 0.49 [5][11].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 78.40 [4][6]. Core Views - The company reported a revenue of HKD 42.854 billion for 1H25, a year-on-year decrease of 2.8%, and an operating profit of HKD 5.192 billion, down 11.3% year-on-year. However, the net profit attributable to shareholders was HKD 5.624 billion, a decline of 5.5%, which exceeded the forecast of HKD 5.381 billion due to gains from the sale of a 50% stake in the Wooreen energy storage project by its Australian subsidiary [1]. - The company is optimistic about future performance growth and dividend increases due to its stable and growth-oriented business model [1][4]. Summary by Sections Financial Performance - In 1H25, the company's operating profit in Hong Kong increased by 8% to HKD 4.447 billion despite a 1.7% decline in electricity sales. This was attributed to ongoing capital expenditures and improvements in fixed asset net value [2]. - The operating profit in mainland China decreased by 13%, primarily due to pressure on electricity prices at the Yangjiang Nuclear Power Station and weak wind resources in some renewable energy projects [2]. - The Australian operations saw an 86% decline in operating profit, impacted by intense retail competition and maintenance shutdowns at power plants [2]. - The company reported a free cash flow of HKD 0.1 billion in 1H25, a significant improvement from a negative HKD 1.3 billion in 1H24 [3]. Future Growth Potential - The company is expanding its zero-carbon project portfolio, with 336 MW of renewable energy capacity commissioned in mainland China and the full commissioning of the Sidhpur wind farm in India [3]. - By 2029, the company aims to achieve approximately 6 GW of renewable energy capacity in mainland China and 3 GW in Australia [3]. - The report emphasizes that the implementation of zero-carbon plans will inject growth potential into the company's performance [3]. Valuation and Estimates - The report adjusts revenue forecasts for Hong Kong, mainland China, and Australia, expecting net profits attributable to shareholders to be HKD 10.670 billion, HKD 11.396 billion, and HKD 12.128 billion for 2025-2027, respectively [4]. - The estimated EPS for 2025 is HKD 4.22, with a projected PB ratio of 1.86x, leading to a target price of HKD 78.40 [4][6].

Group 1: Macroeconomic Overview - In July, high-frequency indicators suggest a rebound in exports before the tariff exemption period, while industrial added value growth may slow down due to overproduction being curbed in some sectors [2][3] - Social financing growth is primarily supported by a year-on-year increase in local government bond issuance, despite weak real estate transaction volumes [2][3] - PPI's year-on-year decline may narrow due to rising commodity prices and a lower base effect, with a more pronounced narrowing expected after August [2][3] Group 2: Fixed Income Market - The credit bond market experienced an overall adjustment from July 18 to July 29, with the largest declines seen in 2-year bonds, followed by 3Y, 5Y, and 10Y bonds [4] - In the recovery phase from July 29 to August 1, short-term bonds showed significant recovery, particularly 1-5Y bonds, while credit bond ETFs faced slight declines [4] - The overall outlook for credit bonds is expected to be moderately bullish, with a positive buying sentiment and potential for further recovery in yields [4] Group 3: Real Estate Sector - The real estate sales scale shows signs of stabilization, but challenges remain due to inventory pressure and price adjustments, leading to a gradual formation of structural differentiation [7] - Policies aimed at stabilizing housing prices and activating demand are expected to gain momentum in the second half of the year [7] Group 4: Automotive Industry - The heavy truck market in China saw wholesale sales of approximately 83,000 units in July, a year-on-year increase of 42%, indicating strong demand driven by "old-for-new" policies [6] - The forecast for heavy truck sales in 2025 has been raised from 1.02 million to 1.05 million units, reflecting a positive industry outlook [6] Group 5: Agricultural Chemicals - Recent policies such as "one certificate, one product" are expected to optimize pesticide quality and market order, potentially reducing the number of brands and enhancing the competitiveness of companies with multiple registration certificates [5] Group 6: Data Center Hardware Opportunities - The development of AI technology is driving a significant increase in demand for computing power, leading to growth in data center hardware investments [9] - There is a growing need for power supply and distribution systems, temperature control systems, and related components, presenting opportunities for domestic replacements and breakthroughs in overseas markets [9] Group 7: Selected Companies - Zhaoyan New Drug has been initiated with a "buy" rating, targeting a price of 37.02 CNY for A shares and 27.34 HKD for H shares, driven by recovery in domestic and overseas markets [11][20] - China Shenhua is planning to acquire 13 core assets from the State Energy Group to enhance resource integration and operational efficiency, with trading expected to resume within 10 days [17]